Nuvation Bio Inc. Files 8-K with Financial Updates
Ticker: NUVB · Form: 8-K · Filed: Nov 17, 2025 · CIK: 1811063
Sentiment: neutral
Topics: financial-reporting, warrants, corporate-actions
Related Tickers: NUVB
TL;DR
Nuvation Bio dropped an 8-K on 11/17/25 - check for warrant and stock details.
AI Summary
Nuvation Bio Inc. filed an 8-K on November 17, 2025, reporting on various events and financial statements. The company, formerly Panacea Acquisition Corp. until April 30, 2020, is incorporated in Delaware and headquartered in New York, NY. The filing includes information related to redeemable warrants and common stock.
Why It Matters
This 8-K filing provides crucial updates on Nuvation Bio's financial status and corporate actions, which are important for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial information and corporate events, not indicating any immediate or significant new risks.
Key Numbers
- 11.50 — Redeemable Warrants Exercise Price (This is the price at which redeemable warrants can be exercised for one share of common stock.)
Key Players & Entities
- Nuvation Bio Inc. (company) — Registrant
- Panacea Acquisition Corp. (company) — Former company name
- November 17, 2025 (date) — Date of report
- April 30, 2020 (date) — Date of name change
- 11.50 (dollar_amount) — Exercise price of redeemable warrants
FAQ
What specific financial statements are included in this 8-K filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific details of these statements are not provided in the excerpt.
What is the exercise price for Nuvation Bio's redeemable warrants?
The exercise price for the redeemable warrants is $11.50 per share.
When did Nuvation Bio Inc. change its name from Panacea Acquisition Corp.?
Nuvation Bio Inc. changed its name from Panacea Acquisition Corp. on April 30, 2020.
What is the primary business of Nuvation Bio Inc. according to its SIC code?
Nuvation Bio Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
What is the filing date of this 8-K report?
The 8-K report was filed on November 17, 2025.
Filing Stats: 910 words · 4 min read · ~3 pages · Grade level 11.6 · Accepted 2025-11-17 17:31:04
Key Financial Figures
- $0.0001 — which registered Class A Common Stock, $0.0001 par value per share NUVB The New Yo
- $11.50 — of Common Stock at an exercise price of $11.50 per share NUVB.WS The New York Stoc
Filing Documents
- d845081d8k.htm (8-K) — 31KB
- d845081dex991.htm (EX-99.1) — 54KB
- g845081ex99_1p10g1.jpg (GRAPHIC) — 204KB
- g845081ex99_1p11g1.jpg (GRAPHIC) — 274KB
- g845081ex99_1p12g1.jpg (GRAPHIC) — 271KB
- g845081ex99_1p13g1.jpg (GRAPHIC) — 239KB
- g845081ex99_1p14g1.jpg (GRAPHIC) — 374KB
- g845081ex99_1p15g1.jpg (GRAPHIC) — 226KB
- g845081ex99_1p16g1.jpg (GRAPHIC) — 306KB
- g845081ex99_1p17g1.jpg (GRAPHIC) — 310KB
- g845081ex99_1p18g1.jpg (GRAPHIC) — 349KB
- g845081ex99_1p19g1.jpg (GRAPHIC) — 287KB
- g845081ex99_1p1g1.jpg (GRAPHIC) — 219KB
- g845081ex99_1p20g1.jpg (GRAPHIC) — 246KB
- g845081ex99_1p21g1.jpg (GRAPHIC) — 201KB
- g845081ex99_1p22g1.jpg (GRAPHIC) — 335KB
- g845081ex99_1p23g1.jpg (GRAPHIC) — 286KB
- g845081ex99_1p24g1.jpg (GRAPHIC) — 219KB
- g845081ex99_1p25g1.jpg (GRAPHIC) — 303KB
- g845081ex99_1p26g1.jpg (GRAPHIC) — 313KB
- g845081ex99_1p27g1.jpg (GRAPHIC) — 175KB
- g845081ex99_1p28g1.jpg (GRAPHIC) — 200KB
- g845081ex99_1p29g1.jpg (GRAPHIC) — 384KB
- g845081ex99_1p2g1.jpg (GRAPHIC) — 459KB
- g845081ex99_1p30g1.jpg (GRAPHIC) — 193KB
- g845081ex99_1p31g1.jpg (GRAPHIC) — 219KB
- g845081ex99_1p32g1.jpg (GRAPHIC) — 169KB
- g845081ex99_1p33g1.jpg (GRAPHIC) — 195KB
- g845081ex99_1p34g1.jpg (GRAPHIC) — 143KB
- g845081ex99_1p35g1.jpg (GRAPHIC) — 234KB
- g845081ex99_1p36g1.jpg (GRAPHIC) — 208KB
- g845081ex99_1p37g1.jpg (GRAPHIC) — 297KB
- g845081ex99_1p38g1.jpg (GRAPHIC) — 331KB
- g845081ex99_1p39g1.jpg (GRAPHIC) — 333KB
- g845081ex99_1p3g1.jpg (GRAPHIC) — 314KB
- g845081ex99_1p4g1.jpg (GRAPHIC) — 276KB
- g845081ex99_1p5g1.jpg (GRAPHIC) — 195KB
- g845081ex99_1p6g1.jpg (GRAPHIC) — 162KB
- g845081ex99_1p7g1.jpg (GRAPHIC) — 228KB
- g845081ex99_1p8g1.jpg (GRAPHIC) — 273KB
- g845081ex99_1p9g1.jpg (GRAPHIC) — 225KB
- 0001193125-25-284845.txt ( ) — 14272KB
- nuvb-20251117.xsd (EX-101.SCH) — 4KB
- nuvb-20251117_def.xml (EX-101.DEF) — 14KB
- nuvb-20251117_lab.xml (EX-101.LAB) — 23KB
- nuvb-20251117_pre.xml (EX-101.PRE) — 15KB
- d845081d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Corporate Presentation of Nuvation Bio Inc. (November 17, 2025) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NUVATION BIO INC. Date: November 17, 2025 By: /s/ Philippe Sauvage Name: Philippe Sauvage Title: Chief Financial Officer